CR20140141A - Proteinas de funcion dual para el tratamiento de desordenes metabolicos - Google Patents

Proteinas de funcion dual para el tratamiento de desordenes metabolicos

Info

Publication number
CR20140141A
CR20140141A CR20140141A CR20140141A CR20140141A CR 20140141 A CR20140141 A CR 20140141A CR 20140141 A CR20140141 A CR 20140141A CR 20140141 A CR20140141 A CR 20140141A CR 20140141 A CR20140141 A CR 20140141A
Authority
CR
Costa Rica
Prior art keywords
treatment
metabolic disorders
dual function
function proteins
proteins
Prior art date
Application number
CR20140141A
Other languages
English (en)
Inventor
Brian R Boettcher
Shari L Caplan
Susan E Cellitti
Douglas S Daniels
Norio Hamamatsu
Bernhard Hubert Geierstanger
Stuart Licht
Andreas Loew
Stephen Craig Weldon
Original Assignee
Novartis Ag
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47023090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140141(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Irm Llc filed Critical Novartis Ag
Publication of CR20140141A publication Critical patent/CR20140141A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a la identificación de nuevas proteínas que comprenden el factor de crecimiento de fibroblastos 21 (FGF21) y otros reguladores metabólicos, incluyendo variantes de los mismos, conocidos por mejorar los perfiles metabólico
CR20140141A 2011-09-26 2014-03-26 Proteinas de funcion dual para el tratamiento de desordenes metabolicos CR20140141A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161539290P 2011-09-26 2011-09-26

Publications (1)

Publication Number Publication Date
CR20140141A true CR20140141A (es) 2014-07-15

Family

ID=47023090

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140141A CR20140141A (es) 2011-09-26 2014-03-26 Proteinas de funcion dual para el tratamiento de desordenes metabolicos

Country Status (27)

Country Link
US (2) US9458214B2 (es)
EP (1) EP2764019B1 (es)
JP (1) JP6152380B2 (es)
KR (1) KR102217254B1 (es)
CN (2) CN106432510A (es)
AP (1) AP2014007544A0 (es)
AR (1) AR088165A1 (es)
AU (1) AU2012316132A1 (es)
BR (1) BR112014007086A2 (es)
CA (1) CA2849760A1 (es)
CL (1) CL2014000737A1 (es)
CO (1) CO6920258A2 (es)
CR (1) CR20140141A (es)
CU (1) CU20140035A7 (es)
EA (1) EA201490697A1 (es)
GT (1) GT201400056A (es)
IL (1) IL231647A0 (es)
MA (1) MA35507B1 (es)
MX (1) MX350840B (es)
PE (1) PE20141542A1 (es)
PH (1) PH12014500659A1 (es)
SG (1) SG11201400596QA (es)
TN (1) TN2014000110A1 (es)
TW (1) TW201315742A (es)
UY (1) UY34347A (es)
WO (1) WO2013049234A2 (es)
ZA (1) ZA201401699B (es)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
PL2726511T3 (pl) 2011-07-01 2019-12-31 Ngm Biopharmaceuticals, Inc. Kompozycje, zastosowania i sposoby leczenia zaburzeń oraz chorób metabolicznych
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
UY34346A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de fusión para tratar trastornos metabólicos
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013172967A1 (en) 2012-05-17 2013-11-21 Extend Biosciences, Inc Carriers for improved drug delivery
TW201420606A (zh) * 2012-08-22 2014-06-01 Lilly Co Eli 同源二聚體蛋白
AU2013311777B2 (en) * 2012-09-07 2018-02-01 Sanofi Fusion proteins for treating a metabolic syndrome
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
EP3798228A1 (en) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
SG11201504815QA (en) 2012-12-27 2015-07-30 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
EP2941267B1 (en) * 2013-01-03 2022-11-16 Oramed Ltd. Compositions for use in treating nafld
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
NZ718962A (en) 2013-10-28 2019-12-20 Ngm Biopharmaceuticals Inc Cancer models and associated methods
AU2015209131B2 (en) 2014-01-24 2020-06-25 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
WO2015138278A1 (en) * 2014-03-11 2015-09-17 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
US11160836B2 (en) * 2014-04-11 2021-11-02 Université Catholique de Louvain Transgenic pig islets and uses thereof for treating diabetes
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
CN114129709A (zh) 2014-10-23 2022-03-04 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
CA2994279A1 (en) 2015-08-04 2017-02-09 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
TW201718629A (zh) * 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
KR102670157B1 (ko) * 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
KR102668200B1 (ko) 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
CA3003616C (en) 2015-11-09 2020-07-28 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
HUE058647T2 (hu) 2016-01-13 2022-09-28 Novo Nordisk As Zsírsav szubsztituenseket tartalmazó EGF(A) analógok
EP3463427A4 (en) 2016-05-25 2020-03-11 Board of Regents, The University of Texas System METHOD AND COMPOSITIONS FOR TREATING SECRETORIC DISEASES
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
WO2018053201A1 (en) 2016-09-14 2018-03-22 Duke University Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
JP2020500150A (ja) 2016-09-23 2020-01-09 デューク ユニバーシティ 下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド
CN110121355B (zh) * 2016-11-10 2023-09-12 株式会社柳韩洋行 用于预防或治疗肝炎、肝纤维化和肝硬化的包含融合蛋白的药物组合物
JP7244923B2 (ja) 2016-11-22 2023-03-23 クロトー セラピューティクス インコーポレイテッド 新規な組換えクロトータンパク質ならびにそれを含む組成物
EP3558341A1 (en) * 2016-12-22 2019-10-30 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
CN108440668A (zh) * 2017-02-16 2018-08-24 瑞阳(苏州)生物科技有限公司 Fgf21与igf-1的融合蛋白及其应用
CN108570109B (zh) * 2017-03-14 2022-04-26 广东东阳光药业有限公司 包含免疫球蛋白Fc部分的双靶点融合蛋白
AU2018256256B2 (en) * 2017-04-21 2023-02-23 Yuhan Corporation Method for producing dual function proteins and its derivatives
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
US11680083B2 (en) 2017-06-30 2023-06-20 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
EP3655427A1 (en) 2017-07-19 2020-05-27 Novo Nordisk A/S Bifunctional compounds
IL274098B2 (en) * 2017-11-06 2024-12-01 Shire Nps Pharmaceuticals Inc Glp-2 analogs and peptibodies for administration before during, or after surgery
CN109836504B (zh) * 2017-11-24 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
WO2019119673A1 (zh) * 2017-12-19 2019-06-27 北京吉源生物科技有限公司 一种双基因修饰的干细胞及其用途
IL275499B2 (en) * 2017-12-22 2024-03-01 Novartis Ag Methods of treating metabolic disorders with fgf21 variants
CN110028587B (zh) * 2018-01-11 2021-10-08 安源医药科技（上海）有限公司 用于调节血糖和脂质的增效型双功能蛋白
WO2019147954A1 (en) 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
AU2019218147B2 (en) * 2018-02-08 2023-06-08 Sunshine Lake Pharma Co., Ltd. FGF21 variant, fusion protein and application thereof
US12257308B2 (en) 2018-04-30 2025-03-25 Duke University Stimuli-responsive PEG-like polymer-based drug delivery platform
CU24554B1 (es) * 2018-05-07 2021-11-04 Ct Inmunologia Molecular Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1
JP2021528422A (ja) * 2018-06-21 2021-10-21 サノフイＳａｎｏｆｉ 最適化された活性比を有するｆｇｆ２１化合物／ｇｌｐ−１ｒアゴニストの組合せ
US12226451B2 (en) 2018-07-03 2025-02-18 Bristol-Myers Squibb Company FGF-21 formulations
US11649275B2 (en) 2018-08-02 2023-05-16 Duke University Dual agonist fusion proteins
JP2022512688A (ja) * 2018-10-24 2022-02-07 シャイア－エヌピーエス ファーマシューティカルズ インコーポレイテッド Ｇｌｐ－２融合ポリペプチドならびに消化管の状態の処置および予防のための使用
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
JP7495420B2 (ja) * 2019-02-20 2024-06-04 ノヴォ ノルディスク アー／エス アミノアシル－ｔＲＮＡ合成酵素およびこの使用
EP3935075A4 (en) * 2019-03-05 2023-01-18 Sunshine Lake Pharma Co., Ltd. POLYPEPTIDE MOLECULE AND APPLICATION THEREOF
CN111944055B (zh) * 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
EP4028413A1 (en) 2019-09-10 2022-07-20 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
CN115322794B (zh) * 2020-01-11 2025-09-19 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
US11981718B2 (en) * 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
CA3181300A1 (en) * 2020-06-03 2021-12-09 Christoffer CLEMMENSEN Glp1r agonist nmdar antagonist conjugates
US20230265152A1 (en) * 2020-07-02 2023-08-24 Sanofi Glp-1r agonist / fgf21 fusion proteins
CN113105561B (zh) * 2021-04-30 2021-12-03 江南大学 一种双靶点融合蛋白的制备方法和应用
KR102631925B1 (ko) * 2021-06-10 2024-02-01 토드제약 주식회사 신규 fgf21 변이체 개발 및 이의 생산기법과 용도
KR20240123816A (ko) * 2021-12-02 2024-08-14 쾨벤하운스 유니버시테트 퇴행성 신경 질환의 치료를 위한 펩티드-약물 접합체
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone
EP4615862A1 (en) * 2022-11-07 2025-09-17 Bp Asset Ix, Inc. Fgf21 protein variant for the treatment of nash
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
CN115991793A (zh) * 2023-01-16 2023-04-21 上海民为生物技术有限公司 具有多重活性的融合蛋白及其应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
ATE110083T1 (de) 1986-05-05 1994-09-15 Gen Hospital Corp Insulinotropes hormon.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE3889853D1 (de) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
EP2163626A1 (en) 1999-11-18 2010-03-17 Novartis Vaccines and Diagnostics, Inc. Human FGF-21 gene and gene expression products
WO2001046261A1 (en) 1999-12-23 2001-06-28 Zymogenetics, Inc. Method for treating inflammation
DK2322631T3 (en) 2001-04-19 2015-01-12 Scripps Research Inst Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA syntetasepar
JP2007531513A (ja) * 2003-11-13 2007-11-08 ハンミ ファーム．インダストリー カンパニー リミテッド 薬物のキャリアとして有用なＩｇＧＦｃ断片およびその製造方法
AU2004303783A1 (en) 2003-12-10 2005-07-07 Eli Lilly And Company Muteins of fibroblast growth factor 21
CN101103045B (zh) 2004-09-24 2015-11-25 安姆根有限公司 修饰的Fc分子
US20080261875A1 (en) * 2005-01-21 2008-10-23 Eli Lilly And Company Method For Treating Cardiovascular Disease
PL2068909T3 (pl) 2007-03-30 2012-09-28 Ambrx Inc Modyfikowane polipeptydy fgf-21 i ich zastosowanie
JP2010535781A (ja) 2007-08-03 2010-11-25 イーライ リリー アンド カンパニー 肥満に対する処置
EP2358749B1 (en) 2008-10-10 2018-07-18 Amgen, Inc Fgf21 mutants and uses thereof
US8785151B2 (en) 2008-10-24 2014-07-22 Bernhard Geierstanger Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
PL2373681T3 (pl) 2008-12-10 2017-07-31 Glaxosmithkline Llc Kompozycje farmaceutyczne albiglutydu
ES2692495T3 (es) 2009-01-23 2018-12-03 Novo Nordisk A/S Derivados del FGF21 con aglutinante de albúmina A-B-C-D-E- y sus usos
CN101812474A (zh) * 2009-02-25 2010-08-25 李慎涛 骨保护素-热休克蛋白65融合蛋白的制备及其应用
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
SMT202400036T1 (it) * 2009-05-05 2024-03-13 Amgen Inc Mutanti fgf21 e loro utilizzi
US20120172298A1 (en) 2009-06-11 2012-07-05 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
CN101993496B (zh) 2009-08-20 2013-06-05 重庆富进生物医药有限公司 双重调节血糖血脂融合蛋白及其制法和用途
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
JP2013514795A (ja) 2009-12-22 2013-05-02 ノバルティス アーゲー 治療における使用のための四価ｃｄ４７抗体定常領域融合タンパク質
EP2359843A1 (en) 2010-01-21 2011-08-24 Sanofi Pharmaceutical composition for treating a metabolic syndrome
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
UY34346A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de fusión para tratar trastornos metabólicos
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
WO2015138278A1 (en) 2014-03-11 2015-09-17 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling

Also Published As

Publication number Publication date
US20130129724A1 (en) 2013-05-23
CO6920258A2 (es) 2014-04-10
SG11201400596QA (en) 2014-09-26
AP2014007544A0 (en) 2014-03-31
GT201400056A (es) 2015-09-23
UY34347A (es) 2013-04-30
JP6152380B2 (ja) 2017-06-21
EP2764019B1 (en) 2019-04-03
ZA201401699B (en) 2015-04-29
IL231647A0 (en) 2014-05-28
CU20140035A7 (es) 2014-08-28
CN106432510A (zh) 2017-02-22
EP2764019A2 (en) 2014-08-13
EA201490697A1 (ru) 2014-11-28
WO2013049234A2 (en) 2013-04-04
KR20140069249A (ko) 2014-06-09
MX2014003676A (es) 2015-03-20
PH12014500659A1 (en) 2014-05-19
PE20141542A1 (es) 2014-10-31
CN104024273B (zh) 2016-10-12
TN2014000110A1 (en) 2015-07-01
US10669323B2 (en) 2020-06-02
AR088165A1 (es) 2014-05-14
AU2012316132A1 (en) 2014-04-17
US9458214B2 (en) 2016-10-04
MA35507B1 (fr) 2014-10-02
WO2013049234A3 (en) 2014-01-03
TW201315742A (zh) 2013-04-16
JP2014527986A (ja) 2014-10-23
BR112014007086A2 (pt) 2017-03-28
CL2014000737A1 (es) 2014-10-03
US20170166621A1 (en) 2017-06-15
MX350840B (es) 2017-09-19
KR102217254B1 (ko) 2021-02-19
CA2849760A1 (en) 2013-04-04
CN104024273A (zh) 2014-09-03

Similar Documents

Publication Publication Date Title
CR20140141A (es) Proteinas de funcion dual para el tratamiento de desordenes metabolicos
UY39119A (es) Proteínas de fusión para tratar trastornos metabólicos
GT201300131A (es) Metodos de tratamiento de trastornos asociados con el fgf21
PE20150201A1 (es) Proteinas del factor 21 de crecimiento del fibroblasto
CO6771447A2 (es) Ciclopropilaminas como inhibidores de desmetilasa 1 específica de lisina
CO6930356A2 (es) Compuestos inhibidores de metaloenzimas
EA201491856A1 (ru) Терапевтическое применение белков фактора роста фибробластов 21
CO6791571A2 (es) Moduladores de la proteína tirosina quinasa 7 (ptk7) para el tratamiento diagnóstico o profilaxis de trastornos neoplásicos
GT201400033A (es) Pirimidinas anilladas sustituidas y uso de las mismas
GT201200250A (es) Ariltriazolonas ligadas a bisarilo y su uso
BR112015000399A2 (pt) derivados de pirazolil pirimidina
UA110880C2 (uk) Заміщені амідином бета-лактами, їх одержання та застосування як антибактеріальних засобів
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
UY34305A (es) Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
GT201500168A (es) Polipéptidos estabilizados del factor de crecimiento tipo insulina
CR20140553A (es) Compuestos de fenoxietil piperidina
MX349254B (es) Compuestos para el tratamiento del sindrome metabolico.
BR112014011481A2 (pt) hidrolisado de colágeno e seu uso
BR112014009760A8 (pt) análogos de ácido siálico
BR112015017432A2 (pt) métodos para o tratamento de indicações cardiovasculares
BR112015003815A2 (pt) métodos e composições para o tratamento de uma condição genética